▎WuXiEdited by Kant Content Team

Kumquat Biosciences today announced a collaboration with Takeda exceeding $1.2 billion, establishing a strategic and exclusive partnership to co-develop and commercialize a novel small-molecule immunomodulatory cancer inhibitor as monotherapy and/or combination therapy.

Kumquat Biosciences is a drug discovery and development company dedicated to creating breakthrough medicines for the treatment of cancer. The company focuses on translating groundbreaking science into potential "first-in-class" and "best-in-class" therapies. Founded in 2019, Kumquat Biosciences has garnered support from leading investors including OrbiMed, Sequoia Capital, EcoR1, Lilly Asia Ventures, and Roche Venture Fund.In 2021, Kumquat Biosciences Inc. entered into a multi-year collaboration agreement with Loxo Oncology, a subsidiary of Eli Lilly and Company., jointly developing novel small molecules with the potential to stimulate tumor-specific immune responses.

According to the terms of the agreement,Kumquat will grant Takeda an exclusive, global license to develop and commercialize selected small molecule inhibitors.According to Kumquat's selection, Takeda will undertake and fund all development and commercialization activities except for the Phase 1 trial activities led by Kumquat.Kumquat Biosciences will receive up to $130 million in near-term payments and is eligible to receive over $1.2 billion in clinical, regulatory, and commercial milestone payments.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate. Retrieved April 16, 2024 from https://www.prnewswire.com/news-releases/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate-302117294.html

[2] Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses. Retrieved April 16, 2024 from https://www.kumquatbiosciences.com/wp-content/uploads/2021/07/Kumquat_Biosciences_and_Lilly_Collaboration.pdf

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress of global biopharmaceuticals and health. This article is for information exchange only, and the views in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.